Gernandt & Danielsson advises Moberg Pharma AB (publ) ("Moberg Pharma") in connection with its fully guaranteed issue of units consisting of ordinary shares and warrants of a maximum of SEK 150 million, with preferential rights for existing shareholders. The rights issue was resolved upon by the Board of Directors on 6 November 2020 and is subject to the approval of an Extraordinary General Meeting.

Gernandt & Danielsson also advises Moberg Pharma in connection with the intended distribution of the business BupiZenge® ("BUPI") to the shareholders in Moberg Pharma by distributing 90 per cent. of the shares in a subsidiary of Moberg Pharma, which will hold BUPI by the time of the distribution, in a so-called Lex ASEA distribution. The Board of Directors of Moberg Pharma has proposed an Extraordinary General Meeting to resolve on the distribution.

Gernandt & Danielsson advises Moberg Pharma with a team consisting of Partner Mikael Borg, Senior Associates Jonas Hämälä and Fredrik Haräng, as well as Associates Jonathan Antonsson, Josefin Törnlöf and Ludvig Eriksson.